All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma

Novel efficacious treatments with long-term tolerability are needed for transplant-ineligible, newly diagnosed multiple myeloma (NDMM) patients. This phase 2 study evaluated the safety and efficacy of all-oral ixazomib-cyclophosphamide-dexamethasone (ICd) followed by single-agent ixazomib maintenance.

Source: European Journal of Cancer - November 22, 2018 Category: Cancer & Oncology Authors: Meletios A. Dimopoulos, Sebastian Grosicki, Wies ław W. Jędrzejczak, Hareth Nahi, Astrid Gruber, Markus Hansson, Neeraj Gupta, Catriona Byrne, Richard Labotka, Zhaoyang Teng, Huyuan Yang, Norbert Grzasko, Shaji Kumar Tags: Original Research Source Type: research